Alzheimer's Diseases – The Newest Medications (2025 AC Live)

Only available as part of a package

Learning Objectives:

Analyze the multifactorial nature of Alzheimer’s disease by evaluating the debated underlying drivers—including amyloid, tau, neuroinflammation, vascular, and metabolic co-pathologies—in order to explain why monoclonal antibody–based amyloid clearance alone is insufficient and why future therapeutic strategies will likely require multi-target approaches.
Evaluate the development and FDA approval of lecanemab and donanemab by analyzing how clinical efficacy endpoints and biomarker validation—such as slowed cognitive decline, PET-detected amyloid clearance, and downstream biomarker changes—converge to support regulatory decisions for disease-modifying therapies.
Apply knowledge of eligibility criteria, dosing regimens, monitoring protocols, and risk–benefit considerations—including ARIA management and mandatory MRI surveillance—to safely implement anti-amyloid therapies for patients with early, biomarker-confirmed Alzheimer’s disease in clinical practice.

Steven Dinsmore, DO, FACOI

Retired

Dr. Steven Dinsmore completed his undergraduate education at Drexel University and earned his medical degree from the Philadelphia College of Osteopathic Medicine. His postgraduate training included an internal medicine residency at the University of Medicine & Dentistry of New Jersey, School of Osteopathic Medicine (UMDNJ-SOM), and he was board certified by the AOBIM. He then completed a neurology residency at the Medical College of Pennsylvania (now Drexel University College of Medicine) and is certified by the ABPN (American Board of Psychiatry and Neurology).

Dr. Dinsmore returned to UMDNJ-SOM and was sponsored by the University as a Special Government Employee for a two-year fellowship in neuromuscular diseases at the National Institutes of Health in Bethesda, MD. He then joined the faculty of the New Jersey Institute for Successful Aging (NJISA) of UMDNJ-SOM, achieving the rank of Associate Professor. At NJISA, he cared for adults aged 55 and older, focusing on neurodegenerative disorders, including a clinic for patients with Post-Poliomyelitis syndrome (1992–1998) and neurological evaluations for the Memory Assessment Program. After 17 years, he transitioned to the U.S. FDA as a Medical Officer in the Office of Neuroscience.

Dr. Dinsmore’s clinical experience in geriatric medicine, interest in the scientific foundations of biomedicine, research at NIH, and facility with information technology enabled a seamless transition into drug development and regulatory science. At FDA he accrued a portfolio of increasingly complex IND (Investigational New Drug Application) and NDA (New Drug Application) regulatory assessments. His work integrated his clinical background in Internal Medicine and Neurology with expanded knowledge in pharmacology, statistics, and toxicology, enabling effective collaboration with multidisciplinary FDA review teams throughout the drug development life cycle. In this role, Dr. Dinsmore developed fluency in the terminology, methodology, and critical analysis central to regulatory science.

Dominic F. Glorioso, Jr., DO, PhD, FACOI, FAAHPM, HMD (he/him/his) (Moderator)

Associate Medical Director, Assistant Clinical Professor of Internal Medicine

Amedisys Hospice, Duquesne University College of Osteopathic Medicine

Dominic F Glorioso Jr, DO PhD FACOI FAAHPM HMD, is the Associate Medical Director of Amedisys Hospice in Harrisburg, PA. He is also an Assistant Clinical Professor of Internal Medicine at the newly launched Duquesne University College of Osteopathic Medicine in Pittsburg, PA. He recently earned a PhD in Healthcare Bioethics from Duquesne University in December of 2023. He has taught medical students since the 1980s as a preceptor in Pensacola, Florida. When he moved to York, PA, in 1997, he frequently had students in his outpatient internal medicine office. In 2003, he became the medical director of VNA Hospice. In 2005, he took the Harvard Course in hospice and palliative care. He received the designation of Faculty Scholar. he then became the Lead Educator for Palliative Care at WellSpan Health System in York. From 2015 until 2019, he was the medical director for palliative care and supportive medicine at UPMC Pinnacle in Harrisburg, PA. Dr. Glorioso is board-certified in Internal Medicine, Hospice, and Palliative Care and is certified as a Hospice Medical Director. He enjoys lecturing about palliative care and healthcare ethics. He also has written a book about healthcare ethics for physicians, nurses, social workers, and chaplains entitled Applying Ethical Principles to Clinical Practice, which should be available later this year.